ImmunityBio, Inc. is an innovative immunotherapy company at the forefront of developing groundbreaking treatments that harness the potential of memory T-cells to address various cancer types. The company's proprietary cancer vaccine represents a significant advancement in oncology, aiming to enhance therapeutic effectiveness while minimizing the need for conventional high-dose chemotherapy. With a strong biotechnology platform and a commitment to redefining cancer treatment, ImmunityBio is well-positioned to lead in the rapidly evolving landscape of cancer therapeutics, ultimately striving to improve patient outcomes and quality of life. Show more
Location: 3530 JOHN HOPKINS COURT, SAN DIEGO, CA, UNITED STATES, 92121, San Diego, CA, 92121, USA | Website: https://immunitybio.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE
Market Cap
6.156B
52 Wk Range
$1.83 - $8.28
Previous Close
$5.91
Open
$5.78
Volume
29,537,843
Day Range
$5.67 - $6.46
Enterprise Value
6.76B
Cash
60.24M
Avg Qtr Burn
-68.91M
Insider Ownership
66.41%
Institutional Own.
15.46%
Qtr Updated
09/30/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
Anktiva (N-803) + BCG Details Non-muscle invasive bladder cancer | Approved Update | |
ANKTIVA (N-803) + tislelizumab, 2L post-CPI Details Non-small cell lung carcinoma | Phase 3 Initiation | |
PD-L1 t-haNK Details Pancreatic cancer | Phase 2/3 Update | |
Phase 2 Data readout | ||
ANKTIVA + adenovirus vaccine Details Lynch Syndrome | Phase 2 Data readout | |
Anktiva (N-803) + PD-L1 CAR-NK (IL-15 Agonist) Details Recurrent Glioblastoma | Phase 2 Update | |
ANKTIVA Details Lymphopenia | Phase 2 Update | |
Anktiva (N-803) + AdHER2DC Details Endometrial cancer | Phase 1/2 Initiation | |
CAR-NK / CD19 t-haNK Details Non-Hodgkin lymphoma | Phase 1 Update | |
N-803 (Anktiva), haNK and Avelumab Details Metastatic merkel cell carcinoma, Insomnia, Mood disorders, Liver transplant, Cancer | Failed Discontinued | |
hAd5-COVID-19 Details Vaccine, COVID-19 | Failed Discontinued |
